Israel Innovation Authority רשות החדשנות
Baruch Stern, Ph.D, serves as a BioTech Analyst at the Israel Innovation Authority since January 2015 and is a Co-Founder of Novel Therapeutics. As CEO and CSO of 3C Biotech, started in May 2013, Baruch Stern focuses on biotechnological enzymatic solutions aimed at global environmental and sustainability challenges. Previous roles include Scientific Director and CSO at Medgenics, Inc. from 2006 to 2012, where Baruch led the clinical trial submissions and secured significant funding, as well as Project Manager at ProChon Biotech Ltd from 2004 to 2006, directing a team in bio-scaffold development. Baruch’s career began with leadership roles at Biogenics Ltd and Sourasky Medical Center, extending back to postdoctoral work at LTIB/NCI/NIH and academic endeavors at the Open University. Baruch Stern earned a Ph.D. in Biology from Tel Aviv University.
This person is not in any offices
Israel Innovation Authority רשות החדשנות
The Israel Innovation Authority is Israel's central agency to manage the country’s governmental support of the resource of innovation. As the governments' operational arm in the arena of technological innovation and R&D, the goal of the Authority is to provide professional support and infrastructure to government efforts to encourage innovation in all industry sectors, complementing the major role that Israel already plays in the global high-tech sector. The Israel Innovation Authority has three main roles: creating infrastructure to support diverse industries, developing tools and programs that suit the needs of the industry, and budgeting and financing high-risk projects and products. In addition to these roles, the Authority serves as a central hub for knowledge and consists of six customer-oriented “Innovation Divisions,” each providing a variety of tools for each market segment and stage in the life cycle of a product: Technological Infrastructure, Advanced Manufacturing, International Collaborations, Societal Challenges, Growth and Early Stage.